Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
06 apr 2016 - 22:00
Statutaire naam
Galapagos NV
Titel
Galapagos initiates a Phase 2a study with GLPG1690 in idiopathic pulmonary fibrosis patients
Bericht
Mechelen, Belgium; 6 April 2016 - Galapagos NV (Euronext & NASDAQ: GLPG) announced the start of its exploratory Phase 2a study with GLPG1690 in idiopathic pulmonary fibrosis (IPF) patients, named FLORA.
FLORA is a randomized, double-blind, placebo-controlled study investigating a once daily oral dose of GLPG1690 administered for 12 weeks in 24 IPF patients. Primary objectives of the study are to assess safety, tolerability, pharmacokinetics and pharmacodynamics of GLPG1690 in an IPF patient population. Target engagement will be measured by LPA in plasma and bronchoalveolar lavage fluid, both at baseline and through twelve weeks of treatment. Secondary objectives include the evaluation of lung function, changes in disease biomarkers and quality of life. Galapagos expects to complete patient recruitment before end 2016, and to report topline results in Q2 2017.
Datum laatste update: 19 februari 2025